Why the study?
Targeting guanylyl cyclase-A with small molecules is attractive for cardiovascular and renal regulation, but drug utilization has been limited to peptides.
Do small molecule allosteric enhancers of GC-A increase ANP/BNP-mediated cGMP production and vasorelaxation in preclinical models?
Population
Various in vitro and ex vivo systems
Comparison
Small molecular allosteric enhancers of GC-A with ANP or BNP
Design
In vitro and ex vivo preclinical study
Authors
Loading...
Preclinical GC-A modulation supports further development; leaves open clinical translation in heart failure.
Do small molecule allosteric enhancers of GC-A increase ANP/BNP-mediated cGMP production and vasorelaxation in preclinical models?
Small molecule allosteric enhancers of GC-A potentiate the effects of ANP and BNP on cGMP production and vasorelaxation, revealing a novel allosteric binding site on GC-A.
Andresen et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: